Paul Fonteyne

Paul Fonteyne began serving as a director of Amylyx in 2021. Mr. Fonteyne has more than thirty years of experience in the pharmaceutical industry, including in leadership positions focused on the commercialization of innovative treatments for patients around the globe. Most notably, he was with Boehringer Ingelheim for over 15 years where he served as the U.S. President and CEO for seven years, then subsequently Chairman until his retirement in January in 2019. During his tenure at Boehringer Ingelheim, Mr. Fonteyne helped drive the company’s annual top line sales in the USA significantly upwards and oversaw the successful U.S. launch of the company’s top selling products. Prior, he held commercial leadership roles at Merck and Co. Inc. from 1994-2003 and Abbott Laboratories from 1987-1995. He has served on the board of PhRMA, chaired the National Pharmaceutical Council and served as Chair of an American Cancer Society initiative for New England known as CEOs against Cancer. Mr. Fonteyne received an M.S. in Chemical Engineering from the University of Brussels and an MBA from Carnegie Mellon University.